Literature DB >> 35970887

Lewis glycosphingolipids as critical determinants of TRAIL sensitivity in cancer cells.

Tomoya Fukuoka1,2, Kenta Moriwaki3, Shinji Takamatsu1, Jumpei Kondo1,4, Miki Tanaka-Okamoto5, Azusa Tomioka6, Manami Semba7,8, Sachiko Komazawa-Sakon7, Yoshihiro Kamada1,9, Hiroyuki Kaji6, Yasuhide Miyamoto5, Masahiro Inoue4, Kazuhiko Bessho2, Yoko Miyoshi2, Keiichi Ozono2, Hiroyasu Nakano7, Eiji Miyoshi10.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cancer cell death and contributes to tumor rejection by cytotoxic lymphocytes in cancer immunosurveillance and immunotherapy. TRAIL and TRAIL receptor agonists have garnered wide popularity as promising agents for cancer therapy. We previously demonstrated that the loss of fucosylation in cancer cells impairs TRAIL sensitivity; however, the precise structures of the fucosylated glycans that regulate TRAIL sensitivity and their carrier molecules remain elusive. Herein, we observed that Lewis glycans among various fucosylated glycans positively regulate TRAIL-induced cell death. Specifically, Lewis glycans on lacto/neolacto glycosphingolipids, but not glycoproteins including TRAIL receptors, enhanced TRAIL-induced formation of the cytosolic caspase 8 complex, without affecting the formation of the membranous receptor complex. Furthermore, type I Lewis glycan expression in colon cancer cell lines and patient-derived cancer organoids was positively correlated with TRAIL sensitivity. These findings provide novel insights into the regulatory mechanism of TRAIL-induced cell death and facilitate the identification of novel predictive biomarkers for TRAIL-related cancer therapies in future.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35970887     DOI: 10.1038/s41388-022-02434-3

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   8.756


  39 in total

Review 1.  TRAIL of Hope Meeting Resistance in Cancer.

Authors:  David Deng; Khalid Shah
Journal:  Trends Cancer       Date:  2020-07-24

2.  Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis.

Authors:  Zhaoyu Jin; Wafik S El-Deiry
Journal:  Mol Cell Biol       Date:  2006-08-28       Impact factor: 4.272

3.  Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  Eugene Varfolomeev; Heather Maecker; Darcie Sharp; David Lawrence; Mark Renz; Domagoj Vucic; Avi Ashkenazi
Journal:  J Biol Chem       Date:  2005-10-15       Impact factor: 5.157

4.  CD95 stimulation results in the formation of a novel death effector domain protein-containing complex.

Authors:  Inna N Lavrik; Thomas Mock; Alexander Golks; Julia C Hoffmann; Simone Baumann; Peter H Krammer
Journal:  J Biol Chem       Date:  2008-07-17       Impact factor: 5.157

5.  Caspase-8 Acts in a Non-enzymatic Role as a Scaffold for Assembly of a Pro-inflammatory "FADDosome" Complex upon TRAIL Stimulation.

Authors:  Conor M Henry; Seamus J Martin
Journal:  Mol Cell       Date:  2017-02-16       Impact factor: 17.970

6.  A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death.

Authors:  Laura S Dickens; Robert S Boyd; Rebekah Jukes-Jones; Michelle A Hughes; Gemma L Robinson; Louise Fairall; John W R Schwabe; Kelvin Cain; Marion Macfarlane
Journal:  Mol Cell       Date:  2012-06-07       Impact factor: 17.970

7.  The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death.

Authors:  Elodie Lafont; Chahrazade Kantari-Mimoun; Peter Draber; Diego De Miguel; Torsten Hartwig; Matthias Reichert; Sebastian Kupka; Yutaka Shimizu; Lucia Taraborrelli; Maureen Spit; Martin R Sprick; Henning Walczak
Journal:  EMBO J       Date:  2017-03-03       Impact factor: 11.598

8.  Cryo-EM structural analysis of FADD:Caspase-8 complexes defines the catalytic dimer architecture for co-ordinated control of cell fate.

Authors:  Joanna L Fox; Michelle A Hughes; Xin Meng; Nikola A Sarnowska; Ian R Powley; Rebekah Jukes-Jones; David Dinsdale; Timothy J Ragan; Louise Fairall; John W R Schwabe; Nobuhiro Morone; Kelvin Cain; Marion MacFarlane
Journal:  Nat Commun       Date:  2021-02-05       Impact factor: 14.919

Review 9.  Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing.

Authors:  Jean Lemoine; Marco Ruella; Roch Houot
Journal:  Clin Cancer Res       Date:  2021-07-12       Impact factor: 13.801

Review 10.  Getting TRAIL back on track for cancer therapy.

Authors:  J Lemke; S von Karstedt; J Zinngrebe; H Walczak
Journal:  Cell Death Differ       Date:  2014-06-20       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.